

Special Issue

Vaccination and Treatments Against Viral Hepatitis: Achievements, Challenges and Perspectives, 2nd Edition

Message from the Guest Editors

Vaccination has been essential in reducing Hepatitis A and B cases in younger age groups in the context of viral hepatitis. In addition, vaccination against HBV, combined with immunoglobulin and prophylactic antiviral use, has resulted in a 90% reduction in cases of mother-to-child transmission and has also helped prevent Hepatitis D infection. Regarding the hepatitis C virus, despite the lack of a vaccine, the use of antiviral treatments has shown promise, and several studies have been conducted to develop an effective vaccine. Vaccination against hepatitis E is only licensed in China, and more safety studies in children, the elderly, and other special populations are needed for future global deployment. This Special Issue aims to collect original research papers and reviews that provide updates on vaccination and treatment methods for viral hepatitis, with research in the following areas: vaccination coverage in the general population and vulnerable populations; new vaccines and treatments, vaccine development, and evaluation; studies in immune escape and immune response; and other related studies that fit the Special Issue's theme.

Guest Editors

Dr. Bárbara Vieira Do Lago

Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro 21040-900, Brazil

Dr. Vinicius M. Mello

Viral Hepatitis Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil

Deadline for manuscript submissions

20 May 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/245076

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).